Roche Holding AG Retained Earnings (Accumulated Deficit) 2010-2024 | RHHBY

Roche Holding AG retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $47.170B, a 26.21% increase year-over-year.

  • Roche Holding AG retained earnings (accumulated deficit) for 2023 were $47.17B, a 15.61% increase from 2022.
  • Roche Holding AG retained earnings (accumulated deficit) for 2022 were $40.802B, a 9.17% increase from 2021.
  • Roche Holding AG retained earnings (accumulated deficit) for 2021 were $37.376B, a 23.11% decline from 2020.

Roche Holding AG Retained Earnings (Accumulated Deficit) 2010-2024 | RHHBY

  • Roche Holding AG retained earnings (accumulated deficit) for 2023 were $47.17B, a 15.61% increase from 2022.
  • Roche Holding AG retained earnings (accumulated deficit) for 2022 were $40.802B, a 9.17% increase from 2021.
  • Roche Holding AG retained earnings (accumulated deficit) for 2021 were $37.376B, a 23.11% decline from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$823.1B
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
AbbVie (ABBV)$348.4B
Novartis AG (NVS)$218.5B
Merck (MRK)$216.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B